<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药明康德 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-07T07:24:53+08:00</updated>
  <subtitle>全球领先的制药、生物技术以及医疗器械研发开放式能力和技术平台，帮助任何人、任何公司更快、更好地研发新医药产品，探索无限可能</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>12/19相聚“云端”！2020药明康德生命化学研究奖即将揭晓</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/PtKZ9pARC1Vg6ESgoG0_iA</id>
    <link href="https://mp.weixin.qq.com/s/PtKZ9pARC1Vg6ESgoG0_iA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH | 展现功能性治愈潜力，CRISPR基因编辑疗法最新结果公布</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/32QX6811pEQAhSp0od02YA</id>
    <link href="https://mp.weixin.qq.com/s/32QX6811pEQAhSp0od02YA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH | 杨森首次公布“first-in-class”双特异性抗体疗法临床结果；BCMA靶向疗法临床结果积极</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/7gtvMn8EVEWHFZVMQcE8eQ</id>
    <link href="https://mp.weixin.qq.com/s/7gtvMn8EVEWHFZVMQcE8eQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH | 克服肿瘤耐药性，差异化非共价BTK抑制剂最新临床结果公布</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/HHg6eKqLI0WtTGUuU1CXmg</id>
    <link href="https://mp.weixin.qq.com/s/HHg6eKqLI0WtTGUuU1CXmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>HER2靶向双特异性抗体获FDA突破性疗法认定；艾伯维10亿美元开发创新蛋白降解疗法</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/EK2gb1tL0LhNHTeQo0cKZw</id>
    <link href="https://mp.weixin.qq.com/s/EK2gb1tL0LhNHTeQo0cKZw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>孤儿药周报 | Claudin 18.2靶向疗法，吉利德TCR疗法入围</title>
    <updated>2020-12-07T07:18:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/yKFtbWhCk_6MUSKYFhG2rA</id>
    <link href="https://mp.weixin.qq.com/s/yKFtbWhCk_6MUSKYFhG2rA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《自然》：用血检确定新冠疫苗的保护效力？科学家完成动物概念验证</title>
    <updated>2020-12-05T07:43:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/8mIsnaGXpMEdzemdQl-mLw</id>
    <link href="https://mp.weixin.qq.com/s/8mIsnaGXpMEdzemdQl-mLw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罕见病专栏 | 一周罕闻药事（11.27-12.4）</title>
    <updated>2020-12-05T07:43:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/MhDENzvmdTeHFZDm5LTZZQ</id>
    <link href="https://mp.weixin.qq.com/s/MhDENzvmdTeHFZDm5LTZZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速递 | “一周一针”索马鲁肽控制体重，诺和诺德使用优先审评券递交监管申请</title>
    <updated>2020-12-05T07:43:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/YKios_T9-B6NHmIoG3l23Q</id>
    <link href="https://mp.weixin.qq.com/s/YKios_T9-B6NHmIoG3l23Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 ASH双抗篇| 再生元、罗氏、强生、辉瑞等公司双特异性抗体疗法将集体亮相！</title>
    <updated>2020-12-05T07:43:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/9ySwuQduhQtGhVo9I5Zfmw</id>
    <link href="https://mp.weixin.qq.com/s/9ySwuQduhQtGhVo9I5Zfmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速递 | FDA批准口服创新疗法，预防遗传性血管水肿发作</title>
    <updated>2020-12-05T07:43:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/SATIpb4UDgShue6XhEx60w</id>
    <link href="https://mp.weixin.qq.com/s/SATIpb4UDgShue6XhEx60w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>致敬时代，感恩有你——写在药明康德成立20周年</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/26gVP5swkcRjIcUtS7slHg</id>
    <link href="https://mp.weixin.qq.com/s/26gVP5swkcRjIcUtS7slHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新20年：那些被人类改变了的疾病 | 致敬时代，感恩有你</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/9J3E7rBBhjhDXBwHt5-Y2g</id>
    <link href="https://mp.weixin.qq.com/s/9J3E7rBBhjhDXBwHt5-Y2g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新20年：造福全球病患的时代 | 致敬时代，感恩有你</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/sDyNZJXx_n6ZBXzvl9Jg4Q</id>
    <link href="https://mp.weixin.qq.com/s/sDyNZJXx_n6ZBXzvl9Jg4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新20年：生命科学的九个突破 | 致敬时代，感恩有你</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/e06d7lxXrUktxbzqScQFQg</id>
    <link href="https://mp.weixin.qq.com/s/e06d7lxXrUktxbzqScQFQg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NEJM：接种90天后中和抗体水平仍高于康复患者，Moderna新冠疫苗持久性最新结果出炉</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/VVWNZOCSFR9NucNtCZzgPQ</id>
    <link href="https://mp.weixin.qq.com/s/VVWNZOCSFR9NucNtCZzgPQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速递 | 杨森递交EGFR/MET双特异性抗体监管申请，治疗特定非小细胞肺癌患者</title>
    <updated>2020-12-04T07:59:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/qE1EbSdPTAEUffgXS9xREw</id>
    <link href="https://mp.weixin.qq.com/s/qE1EbSdPTAEUffgXS9xREw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药明康德荣膺弗若斯特沙利文“2020全球客户价值领导力奖” | Bilingual News</title>
    <updated>2020-12-03T07:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/6Cg2-sBEw8yX9ViEDULGFg</id>
    <link href="https://mp.weixin.qq.com/s/6Cg2-sBEw8yX9ViEDULGFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速递 | 辉瑞/BioNTech新冠疫苗在英国首先获紧急使用授权</title>
    <updated>2020-12-03T07:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/MQjLJeIA46q0ww4XB52bvg</id>
    <link href="https://mp.weixin.qq.com/s/MQjLJeIA46q0ww4XB52bvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速递 | 10亿美元开发创新蛋白降解疗法，艾伯维达成研发合作</title>
    <updated>2020-12-03T07:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/TFiTR2MwzsX_1zCftHPPeA</id>
    <link href="https://mp.weixin.qq.com/s/TFiTR2MwzsX_1zCftHPPeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>